Support from global consortium will expand access to shorter TB prevention options, help advance efforts towards TB elimination
Johannesburg, 24 March 2023 – The Unitaid-funded IMPAACT4TB Consortium, led by the Aurum Institute, announced today that it will provide 250,000 patient courses of short course rifapentine-based preventive treatment regimens to seven countries to help prevent tuberculosis (TB). The patient courses will include the three-month 3HP regimen, and the even shorter 1HP, that is only taken for 28 days. This contribution is part of the Consortium's ongoing efforts to end TB and improve global health outcomes.